Overview Dividends

(DLB) Dolby Laboratories - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US25659T1079

Audio Codecs, Video Codecs, Cinema Hardware, Cloud Platform

DLB EPS (Earnings per Share)

EPS Growth (3Y CAGR): -60.87%
EPS Trend (3Y Correlation): -34.6%

DLB Revenue

Revenue Growth (3Y CAGR): 4.69%
Revenue Trend (3Y Correlation): 25.5%

Description: DLB Dolby Laboratories November 04, 2025

Dolby Laboratories (NYSE:DLB) designs and licenses audio- and video-codec technologies-including AAC, HE-AAC, Dolby Atmos, Dolby Vision, DD+, AC-4 and HEVC-and sells premium cinema solutions (Dolby Cinemas) and a SaaS platform (Dolby.io) that powers real-time immersive experiences for live events, streaming, and broadcast. Its product portfolio spans hardware (servers, processors, amplifiers, loudspeakers) and software used by film studios, content creators, post-production houses, broadcasters, and live-entertainment venues worldwide.

Key quantitative signals (as of FY 2023) show total revenue of roughly $1.6 billion, with licensing contributing about 55 % and the newer Dolby.io SaaS business growing at a compound annual rate of ~30 % YoY. The company’s operating margin hovered near 20 %, and its cash conversion cycle is under 45 days, reflecting strong recurring cash flows. Sector-wide, the immersive-media market is projected to expand >10 % CAGR through 2028, driven by rising streaming adoption, 5G rollout, and premium-home-theater upgrades-trends that directly boost demand for Dolby’s codecs and premium cinema offerings.

For a deeper, data-driven look at how Dolby’s growth catalysts compare to peer benchmarks, you might explore the analyst tools on ValueRay to surface additional valuation and risk metrics.

DLB Stock Overview

Market Cap in USD	6,456m
Sub-Industry	Electronic Components
IPO / Inception	2005-02-17

DLB Stock Ratings

Growth Rating	-37.8%
Fundamental	67.1%
Dividend Rating	58.4%
Return 12m vs S&P 500	-23.5%
Analyst Rating	4.50 of 5

DLB Dividends

Dividend Yield 12m	2.03%
Yield on Cost 5y	1.64%
Annual Growth 5y	8.73%
Payout Consistency	86.1%
Payout Ratio	32.4%

DLB Growth Ratios

Growth Correlation 3m	-89.9%
Growth Correlation 12m	-70.1%
Growth Correlation 5y	-47.3%
CAGR 5y	-1.07%
CAGR/Max DD 3y (Calmar Ratio)	-0.04
CAGR/Mean DD 3y (Pain Ratio)	-0.11
Sharpe Ratio 12m	-1.20
Alpha	-27.80
Beta	0.918
Volatility	21.67%
Current Volume	507.8k
Average Volume 20d	491.2k
Stop Loss	63.1 (-3.1%)
Signal	-0.69

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (264.3m TTM) > 0 and > 6% of Revenue (6% = 80.8m TTM)

FCFTA 0.14 (>2.0%) and ΔFCFTA 4.79pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 70.48% (prev 88.46%; Δ -17.98pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.23 (>3.0%) and CFO 747.2m > Net Income 264.3m (YES >=105%, WARN >=100%)

Net Debt (-435.1m) to EBITDA (306.4m) ratio: -1.42 <= 3.0 (WARN <= 3.5)

Current Ratio 3.44 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (95.8m) change vs 12m ago -1.21% (target <= -2.0% for YES)

Gross Margin 88.52% (prev 88.72%; Δ -0.20pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 43.66% (prev 42.35%; Δ 1.31pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 7.11 (EBITDA TTM 306.4m / Interest Expense TTM 34.1m) >= 6 (WARN >= 3)

Altman Z'' 9.80

(A) 0.30 = (Total Current Assets 1.34b - Total Current Liabilities 388.8m) / Total Assets 3.20b

(B) 0.82 = Retained Earnings (Balance) 2.62b / Total Assets 3.20b

warn (B) unusual magnitude: 0.82 — check mapping/units

(D) 4.43 = Book Value of Equity 2.62b / Total Liabilities 591.3m

Total Rating: 9.80 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 67.14

1. Piotroski 6.50pt = 1.50

2. FCF Yield 7.55% = 3.77

3. FCF Margin 32.52% = 7.50

4. Debt/Equity 0.02 = 2.50

5. Debt/Ebitda -1.42 = 2.50

6. ROIC - WACC (= -1.34)% = -1.68

7. RoE 10.40% = 0.87

8. Rev. Trend 25.47% = 1.91

9. EPS Trend -34.65% = -1.73

What is the price of DLB shares?

As of November 09, 2025, the stock is trading at USD 65.11 with a total of 507,786 shares traded.
Over the past week, the price has changed by -1.82%, over one month by -6.89%, over three months by -9.13% and over the past year by -12.71%.

Is Dolby Laboratories a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Dolby Laboratories (NYSE:DLB) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 67.14 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DLB is around 57.97 USD . This means that DLB is currently overvalued and has a potential downside of -10.97%.

Is DLB a buy, sell or hold?

Dolby Laboratories has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy DLB.

Strong Buy: 2
Buy: 2
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the DLB price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	95.8	47.1%
Analysts Target Price	95.8	47.1%
ValueRay Target Price	65.1	0%

DLB Fundamental Data Overview October 27, 2025

Market Cap USD = 6.46b (6.46b USD * 1.0 USD.USD)
P/E Trailing = 24.8561
P/E Forward = 17.452
P/S = 4.7932
P/B = 2.6313
P/EG = 2.0755
Beta = 0.918
Revenue TTM = 1.35b USD
EBIT TTM = 242.1m USD
EBITDA TTM = 306.4m USD
Long Term Debt = 39.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 12.2m USD (from shortTermDebt, last fiscal year)
Debt = 47.0m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -435.1m USD (from netDebt column, last fiscal year)
Enterprise Value = 5.80b USD (6.46b + Debt 47.0m - CCE 698.6m)
Interest Coverage Ratio = 7.11 (Ebit TTM 242.1m / Interest Expense TTM 34.1m)
FCF Yield = 7.55% (FCF TTM 438.1m / Enterprise Value 5.80b)
FCF Margin = 32.52% (FCF TTM 438.1m / Revenue TTM 1.35b)
Net Margin = 19.62% (Net Income TTM 264.3m / Revenue TTM 1.35b)
Gross Margin = 88.52% ((Revenue TTM 1.35b - Cost of Revenue TTM 154.6m) / Revenue TTM)
Gross Margin QoQ = 86.06% (prev 90.30%)
Tobins Q-Ratio = 1.82 (Enterprise Value 5.80b / Total Assets 3.20b)
Interest Expense / Debt = 72.52% (Interest Expense 34.1m / Debt 47.0m)
Taxrate = 16.16% (8.97m / 55.5m)
NOPAT = 203.0m (EBIT 242.1m * (1 - 16.16%))
Current Ratio = 3.44 (Total Current Assets 1.34b / Total Current Liabilities 388.8m)
Debt / Equity = 0.02 (Debt 47.0m / totalStockholderEquity, last quarter 2.60b)
Debt / EBITDA = -1.42 (Net Debt -435.1m / EBITDA 306.4m)
Debt / FCF = -0.99 (Net Debt -435.1m / FCF TTM 438.1m)
Total Stockholder Equity = 2.54b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.27% (Net Income 264.3m / Total Assets 3.20b)
RoE = 10.40% (Net Income TTM 264.3m / Total Stockholder Equity 2.54b)
RoCE = 9.39% (EBIT 242.1m / Capital Employed (Equity 2.54b + L.T.Debt 39.1m))
RoIC = 7.99% (NOPAT 203.0m / Invested Capital 2.54b)
WACC = 9.33% (E(6.46b)/V(6.50b) * Re(9.40%) + (debt cost/tax rate unavailable))
Discount Rate = 9.40% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.85%
[DCF Debug] Terminal Value 73.62% ; FCFE base≈368.9m ; Y1≈371.9m ; Y5≈400.9m
Fair Price DCF = 91.41 (DCF Value 5.59b / Shares Outstanding 61.2m; 5y FCF grow 0.37% → 3.0% )
EPS Correlation: -34.65 | EPS CAGR: -60.87% | SUE: -4.0 | # QB: 0
Revenue Correlation: 25.47 | Revenue CAGR: 4.69% | SUE: 0.10 | # QB: 0

Additional Sources for DLB Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle